NOT YET RECRUITING
NCT07467434
FOLFIRINOX Induction Chemotherapy for Synchronous Liver Metastases
SYNCHRONOX is a multicenter cohort (retrospective then prospective) intending to include 550 patients with mid or low rectal adenocarcinoma (pMMR, T3-T4 and/or N+) and resectable synchronous liver metastases, treated upfront with at least two cycles of induction FOLFIRINOX chemotherapy. The primary objective is to determine, at 18 months, the R0 resection rate of both tumor sites (rectum and liver), while secondary objectives focus on 3 year overall and progression free survival, radiological and pathological responses, postoperative morbidity and mortality, and comparison of the different surgical strategies after FOLFIRINOX.
Gender: All
Ages: 18 Years - Any
Rectal Cancer
Synchronous Liver Metastases
Antineoplastic Combined Chemotherapy Protocols
+1